Drug Trial Radar · NCT05196399
Bioequivalence Study of Different Aprocitentan Tablet Formulations
Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Feb 2, 2022
Primary completion
Mar 27, 2022
Study completion Apr 7, 2022
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.
Conditions
- Healthy Subjects
Interventions
Aprocitentan (Formulation A)Drug
A single oral dose of 25 mg.
Aprocitentan (Formulation B)Drug
A single oral dose of 25 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
- The area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
- Area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of aprocitentanTime frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CEPHA s.r.o.
Pilsen, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.